Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
Dateline City:
PHILADELPHIA
Data Formed the Basis for KEYTRUDA U.S. FDA Submission and Breakthrough Therapy Designation in Advanced NSCLC
PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced new data from KEYNOTE-001, a Phase 1b study evaluating
KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy,
in naïve and previously-treated patients with advanced non-small cell
lung cancer (NSCLC).
...
Source: Merck.com - Corporate News - April 19, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
Dateline City:
PHILADELPHIA
...in a Phase 3 Study of Patients with Advanced Melanoma
Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
Merck Plans to Submit sBLA for First-Line Indication in Advanced Melanoma in Mid-2015
PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from the randomized, pivotal Phase 3 study,
...
Source: Merck.com - Corporate News - April 19, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the company has submitted a supplemental Biologics
License Application to the U.S. Food and Drug Administration (FDA) for
KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy,
for the treatment of advanced non-small cell lung cancer (NSCLC).
Language:
English
Contact:
...
Source: Merck.com - Corporate News - April 19, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
Dateline City:
KENILWORTH, N.J. & AMES, Iowa
rVSV-ZEBOV-GP (V920) Now Being Studied in Three Key Safety and Efficacy Clinical Trials
KENILWORTH, N.J. & AMES, Iowa--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
NewLink Genetics Corporation (NASDAQ: NLNK), confirmed today that the
third, late-stage, clinical trial of their Ebola vaccine candidate
rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine
candidat...
Source: Merck.com - Corporate News - April 14, 2015 Category: Pharmaceuticals Tags: Ebola Newsroom Corporate News Latest News Source Type: news
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for the Treatment of Advanced Prostate Cancer
Dateline City:
PRINCETON, N.J., and KENILWORTH, N.J.
KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and...
Source: Merck.com - Corporate News - April 8, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015
Dateline City:
KENILWORTH, N.J.
Congress Highlights Include Results from Trials in a Wide Range of HCV Patients -- Patients with Chronic Kidney Disease, HIV Co-infection, Cirrhosis, and Prior Treatment Failures
Company Remains on Track for NDA Filing with the U.S. FDA During First Half of 2015
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic ...
Source: Merck.com - Corporate News - April 8, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015
Dateline City:
KENILWORTH, N.J.
Congress Highlights Include Results from Trials in a Wide Range of HCV Patients -- Patients with Chronic Kidney Disease, HIV Co-infection, Cirrhosis, and Prior Treatment Failures
Company Remains on Track for NDA Filing with the U.S. FDA During First Half of 2015
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced that grazoprevir/elbasvir, an investigational...
Source: Merck.com - Corporate News - April 8, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News Source Type: news
Merck Receives 2015 ENERGY STAR Sustained Excellence Award from U.S. Environmental Protection Agency
Dateline City:
KENILWORTH, N.J.
Company Receives EPA Honor for 10th Consecutive Year
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that it has received an ENERGY STAR 2015 Partner of the
Year – Sustained Excellence Award from the U.S. Environmental Protection
Agency (EPA) for its continued improvement of energy performance and
leadership in energy management in both the pharmaceutical and
...
Source: Merck.com - Corporate News - April 6, 2015 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
will hold its first-quarter 2015 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EDT on Tuesday, April
28. During the call, company executives will provide an overview of
Merck’s performance for the quarter.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - March 27, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Announces New $10 Billion Share Repurchase Program
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that its board of directors has authorized additional
purchases of up to $10 billion of Merck’s common stock for its treasury.
The treasury stock purchase has no time limit and will be made over time
in open-market transactions, block transactions on or off an exchange,
or in privately negotiated transactions.
Language:
English ...
Source: Merck.com - Corporate News - March 24, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early
Dateline City:
KENILWORTH, N.J.
KEYTRUDA Demonstrated Superior Overall Survival and Progression-Free Survival Compared to Ipilimumab
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the randomized, pivotal Phase 3 study (KEYNOTE-006)
investigating KEYTRUDA® (pembrolizumab) compared to
ipilimumab in the first-line treatment of patients with advanced
melanoma has met its two primary endpoin...
Source: Merck.com - Corporate News - March 24, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
New Data Investigating Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
Dateline City:
KENILWORTH, N.J.
Data to be Presented Across Multiple Tumor Types for KEYTRUDA and MK-8628 (OTX015), an Investigational BET-Bromodomain Inhibitor
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data evaluating KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, in both advanced
non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma
will be pres...
Source: Merck.com - Corporate News - March 18, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
KEYTRUDA® (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma
Dateline City:
KENILWORTH, N.J.
EAMS Aims to Give U.K. Patients Access to Promising, Innovative Treatments Prior to European License
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the company’s anti-PD-1 therapy, pembrolizumab,
which is marketed in the U.S. under the name KEYTRUDA®, is
the first treatment to be accepted under the U.K.’s new Early Access to
Medicines Scheme (EAMS). P...
Source: Merck.com - Corporate News - March 11, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Merck to Present at the Barclays Global Healthcare Conference
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Robert Davis, executive vice president and chief
financial officer, Merck, is scheduled to present at the Barclays Global
Healthcare Conference in Miami on March 11, 2015 at 8:00 a.m. EDT.
Investors, analysts, members of the media and the general public are
invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/webcasts-and-presentations....
Source: Merck.com - Corporate News - March 10, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Present at the 35th Annual Cowen Health Care Conference
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Adam Schechter, executive vice president and
president, Global Human Health, Merck, is scheduled to present at the 35th
Annual Cowen Health Care Conference in Boston on Mar. 3, 2015 at 8:40
a.m. EST. Investors, analysts, members of the media and the general
public are invited to listen to a live audio webcast of the presentation
at http://www.merck.com/investors/events-an...
Source: Merck.com - Corporate News - March 2, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
